<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-057465</identifier>
<setSpec>0212-1611</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Morbid obesity, non-alcoholic fatty liver disease, metabolic syndrome and bariatric surgery</dc:title>
<dc:description xml:lang="en">Objectives: The objectives of the present study are: 1) to assess protein changes in patients diagnosed with morbid obesity (MO) and non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH); 2) to assess the likely reversibility of these entities after bariatric surgery, and 3) to analyze their progression seven years after the gastric bypass.  Material and methods: We retrospectively analyzed the data from 190 patients, 150 women (79%) and 40 men (21%) diagnosed with MO and surgically treated at our Hospital (Capella&#146;s gastric bypass). Mean age of the patients was 36.5 years (range: 18.5-54.5). Anthropometric values are gathered: body mass index (BMI), waist circumference (WC) and biochemistry: insulin (INS), glucose (GLU), total proteins (TP), albumin (ALB), transferrin (TRF), ferritin (FER), prealbumin (PBA), retinol binding protein (RBP) and C reactive protein (CRP). The HOMA index was calculated before the bypass and at the following follow-up periods after bypass: 6, 12, 60 and 84 months.  Results: Abdominal ultrasound suggesting NAFLD or  NASH was found in 34.7% (n = 66; 52 women and 14 men) of MO patients surgically treated. Ninety patients (47.3%; 67 women and 23 men) presented risk factors for metabolic syndrome (MS). All patients with possible liver dysfunction had MS. Before the bypass, we found increased levels of: BMI, WC, CRP, GLU, INS and HOMA index and changes in TP, ALB, PBA, RBP, FER and TRF levels. The first set of parameters start to decrease within 6 months after        surgical bypass and at the same time the changes in protein levels start to face off and remain stable at 84  months. Conclusions: Weight loss due to bariatric surgery represents an effective method of fighting MO and its associated comorbidities (NAFLD, NASH, hyperinsulinemia, hyperglycemia, dyslipidemia and components of the metabolic syndrome)</dc:description>
<dc:creator>Criado, L</dc:creator>
<dc:creator>Marco, A</dc:creator>
<dc:creator>Aguirregoicoa, E</dc:creator>
<dc:creator>Rodríguez, A</dc:creator>
<dc:creator>Ruano, M</dc:creator>
<dc:creator>García-Blanch, G</dc:creator>
<dc:creator>Silvestre, V</dc:creator>
<dc:creator>García-Lescún, MCG</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos: Los objetivos del presente estudio son: 1) evaluar las alteraciones proteicas en pacientes: diagnosticados de obesidad mórbida (OM) y portadores de hígado graso no alcohólico (NAFLD) o esteatohepatitis (NASH); 2) valorar la posible reversibilidad de las mismas tras cirugía bariátrica, y 3) analizar su evolución tras siete años de realizado el bypass gástrico. Material y métodos: Evaluamos retrospectivamente los datos de 190 pacientes, 150 mujeres (79%) y 40 hombres (21%) diagnosticados de OM e intervenidos quirúrgicamente en nuestro Hospital (bypass gástrico de Capella). La edad media de los pacientes fue de 36,5 años (rango: 18,5-54,5). Se recogen variables antropométricas: índice de masa corporal (IMC), circunferencia de la cintura (CC) y bioquímicas: niveles de insulina (INS), glucosa (GLU), proteína totales (PT), albúmina (ALB), transferrina (TRF), ferritina (FER), prealbúmina (PBA), proteína ligadora de retinol (RBP) y proteína C reactiva (PCR). Se calcula el índice HOMA previo al bypass y con tiempos de seguimiento de 6, 12, 60 y 84 meses de realizado el bypass. Resultados: La ecografía abdominal sugestiva de sufrir NAFLD o NASH se encontró en el 34,7% (n = 66; 52 mujeres y 14 hombres) de los pacientes con OM intervenidos quirúrgicamente. En 90 pacientes (47,3%; 67 mujeres y 23 hombres) se pudo demostrar que eran portadores  de los factores de riesgo de síndrome metabólico (SM). Todos los pacientes con posible disfunción hepática eran portadores del SM. Previo al bypass encontramos niveles elevados de: IMC, CC, PCR, GLU, INS e índice HOMA y alteraciones en los niveles de PT, ALB, PBA, RBP, FER y TRF. Los primeros, comienzan a descender a los 6 meses de realizado el bypass al mismo tiempo las alteraciones de los niveles proteicos comienzan a desaparecer y continúan estables a los 84 meses de realizado.  Conclusiones: La pérdida de peso por la cirugía bariátrica        constituye el método más eficaz en la lucha contra la OM y sus comorbilidades (NAFLD, NASH, hiperinsulinemia, hiperglucemia, dislipemia y componentes del síndrome metabólico)</dc:description>
<dc:source>Nutr Hosp;22(5): 602-606, sept.-oct. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-057465</dc:identifier>
<dc:title xml:lang="es">Obesidad mórbida, enfermedad de hígado graso no alcohólico, síndrome metabólico y cirugía bariátrica</dc:title>
<dc:subject>^d23640^s22074</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d19272^s22009</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5337^s22012</dc:subject>
<dc:subject>^d27937</dc:subject>
<dc:subject>^d36032^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d19272^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>200710</dc:date>
</metadata>
</record>
</ibecs-document>
